Brief: Cabaletta Bio Receives FDA Clearance Of Ind Application For Caba-201 For Treatment Of Systemic Lupus Erythematosus
31/03/2023 12:08
March 31 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
CABA-201 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
* CABALETTA BIO INC - PLANS TO INITIATE A PHASE 1/2 CLINICAL
TRIAL
OF CABA-201 FOR TREATMENT OF SLE IN PATIENTS WITH ACTIVE LUPUS
NEPHRITIS
Source text for Eikon: ID:nGNX4227FQ
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity